Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry.
about
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesTargeted killing of virally infected cells by radiolabeled antibodies to viral proteinsOligomer-specific conformations of the human immunodeficiency virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodiesA novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteinsAntibody neutralization escape mediated by point mutations in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1.Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes.Inhibition of human immunodeficiency virus type 1 replication prior to reverse transcription by influenza virus stimulation.Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution.Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120Anti-idiotypic monobodies derived from a fibronectin scaffold.Residues in the membrane-spanning domain core modulate conformation and fusogenicity of the HIV-1 envelope glycoprotein.Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence.Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees.Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells.Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodiesIdentification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.The efficacy of T cell-mediated immune responses is reduced by the envelope protein of the chimeric HIV-1/SIV-KB9 virus in vivo.Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trialAn HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum.Human immunodeficiency virus type 1 evades T-helper responses by exploiting antibodies that suppress antigen processingA broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes.Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptorRemoval of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responsesConserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding SitesAntibodies to several conformation-dependent epitopes of gp120/gp41 inhibit CCR-5-dependent cell-to-cell fusion mediated by the native envelope glycoprotein of a primary macrophage-tropic HIV-1 isolate.Antibody-DEPENDENT, FcγRI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis.HIV-1 Antigens in Neurons of Cocaine-Abusing PatientsInduction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo.Human Immunodeficiency Virus and Simian Immunodeficiency Virus Maintain High Levels of Infectivity in the Complete Absence of Mucin-Type O-Glycosylation.Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent MannerImmunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIVAutologous and heterologous neutralization analyses of primary feline immunodeficiency virus isolates.
P2860
Q24561905-E6A0E87B-3FB1-4D80-BD23-96E707BBE285Q28469068-CD2DC73D-3D7E-467C-8682-FAEED8783C3DQ30436401-B9C1F79F-11CB-4095-9C1E-5F5C89E01BCEQ31143293-72261336-3341-4031-B31A-396115F356FFQ33653001-C06306F0-2A68-404F-B011-4BF73887466DQ33781344-E3481614-E93C-4C65-B9F5-CA0B3D6FF60FQ33785510-2EACBE66-055B-41E7-A476-949F720C8E66Q33787329-4658522A-F229-4AA3-B2C9-F46C808FDBB4Q33804258-1E10DA15-60AD-4C98-BAE8-CDA0890706EDQ33804811-EE956259-F3A6-40EA-A752-94A3E81F5F8AQ33807129-41EBF558-20F8-4338-B369-96F4974EC609Q33809112-B7302600-B43F-4688-8FE4-EF512C134AEFQ33842152-EB86E058-B378-4C2E-BFD4-E20DED485F19Q33849085-CE48863C-071D-4C3A-B2EF-444D33FCA2C9Q33876210-A2AF5E01-5B51-4EFC-B7CF-40EF49AC3772Q33987533-2EF529BF-5533-468C-87B4-7D1358D5EF74Q34016706-05C497EA-27E1-4F60-B43C-0DC545FF106BQ34069214-517B7ACA-1DB8-4B57-93E7-7B8425567529Q34338761-DF48A716-6B91-41FF-A30D-A6577F482760Q34374835-4130CEF9-736D-49EF-A3A4-C27156FB093CQ34392963-636C63F2-91BF-456A-AE80-FAC9C7B6162FQ34406977-660BDCF2-4526-4E2A-A620-2C0B2825B332Q34535707-23BC371D-D232-488D-9546-43E46665E2BAQ34562259-35C4FF91-E286-47CD-B04C-79B8A2E0A106Q35077677-06EE68B6-E18B-4C78-B61A-C54661526470Q35122914-206D6484-2CAC-4E6B-98D5-BF0140A4E52AQ35706462-975D5EF6-95F6-47C2-8947-AACBADE7ED6BQ35853750-EF8A8019-9849-4756-8D8B-40BE35D5B6EEQ35890867-036007A7-1CC7-4EFD-82D1-F493E2B0DC0FQ36424574-78F607FA-5A79-4D15-BD51-E049665B6639Q36434294-37FDF29C-D92E-463C-A091-5F8BAAF4B1AFQ36565346-A4D0E010-86F2-4D88-8AE3-453C95CCC978Q36760004-C19035FD-2BF4-423D-94B3-A64FA44A56A5Q37183625-0ABEB6ED-90D2-4A12-8214-2E5084604955Q37252966-F610D4BE-5280-4F37-BFF5-4D4D42614096Q38652858-3778F8BF-ACC0-4F88-BFE9-C26E850A9055Q38659327-1EEE8BF1-9429-4DA0-9CEA-E6D760F16AA2Q38719420-1BEAC7D3-2CB6-46E3-AA65-33B642C9D786Q39550518-30583E9F-60E4-48D1-A337-1F73FCD282BEQ39577849-2AC0C683-7143-4C56-82D9-DA9B8A4D754A
P2860
Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Serotyping of primary human im ...... c locations by flow cytometry.
@ast
Serotyping of primary human im ...... c locations by flow cytometry.
@en
type
label
Serotyping of primary human im ...... c locations by flow cytometry.
@ast
Serotyping of primary human im ...... c locations by flow cytometry.
@en
prefLabel
Serotyping of primary human im ...... c locations by flow cytometry.
@ast
Serotyping of primary human im ...... c locations by flow cytometry.
@en
P2093
P2860
P1433
P1476
Serotyping of primary human im ...... ic locations by flow cytometry
@en
P2093
P2860
P304
P407
P577
1995-06-01T00:00:00Z